Advancing treatments for transthyretin amyloid cardiomyopathy: Innovations in RNA silencing, gene editing, TTR stabilization, and degradation

Kardiol Pol. 2025 Jan 7. doi: 10.33963/v.phj.104054. Online ahead of print.
No abstract available